[Skip navigation]FDA Logo links to FDA home page
Center for Drug Evaluation and Research, U.S. Food and Drug AdministrationU.S. Food and Drug AdministrationCenter for Drug Evaluation and Research
  HHS Logo links to Department of Health and Human Services website

FDA Home Page | CDER Home Page | CDER Site Info | Contact CDER | What's New @ CDER

horizonal rule

DEPARTMENT OF HEALTH & HUMAN SERVICES Public Health Service
Food and Drug Administration, College Park, Maryland 20740

U.S. Department of Health and Human Services symbol

 

 

June 23, 2003

CERTIFIED MAIL
RETURN RECEIPT REQUESTED

The Power Store
1011 North Galena Avenue
Dixon, Illinois 61021

Ref. No. CL-03-HFS-810-52

Dear Sir or Madam:

This is to advise you that the Food and Drug Administration (FDA) has reviewed your web site at the Internet address: http://www.thepowerstore.com and has determined that the products "Omega Twin Flax Borage - Barleans," "High Lignan Flax Oil - Barleans," "Yeast Fighters - Twinlab," "E Super Complex 1, 0000 Iu- Twinlab," "Omega 3 Fish Oil - Twinlab," "C 1000 Caps - Twinlab," "C+ Citrus Bioflavonoid - Twinlab," "Potassium 99 mg - Twinlab," "Magnesium 400 mg - Twinlab," and "Emergen C Tangerine - Alacer" being offered are promoted for conditions that cause the products to be drugs under section 201(g)(1) of the Federal Food, Drug, and Cosmetic Act (the Act) [21 USC 321(g)(1)]. The therapeutic claims on your web site establish that the products are drugs because they are intended for use in the cure, mitigation, treatment, or prevention of disease. The continued marketing of these products with these claims violates the Act and may subject you or the products to regulatory action without further notice.

Examples of some of the claims observed on your web site include:

Omega Twin Flax Borage - Barleans

".reduce blood pressure, decrease arthritis pain, lower cholesterol and reduce the risk of blood clot formation."

High Lignan Flax Oil - Barleans

".reduce blood pressure, decrease arthritis pain, lower cholesterol and reduce the risk of blood clot formation."

Yeast Fighters - Twinlab

".lower 'bad' cholesterol."

E Super Complex 1,000 Iu - Twinlab

"Antioxidant important in the prevention of cancer & Cardiovascular Disease."."reduces blood pressure, aids in preventing cataracts.."Omega 3 Fish Oil - Twinlab

".reduce blood pressure, decrease arthritis pain, lower cholesterol and reduce the risk of blood clot formation."

C 1000 Caps - Twinlab

".may help protect against certain cancers, cataracts and heart disease."

C+citrus Bioflavonoid - Twinlab

".may help protect against certain cancers, cataracts and heart disease."

Potassium 99 mg - Twinlab

".helps prevent stroke,."

Magnesiumm 400 mg - Twinlab

".prevent depression,."

Emergen C Tangerine - Alacer

"Promotes.wound healing, and resistance to infections." ".protect against certain cancers, cataracts and heart disease."


Furthermore, FDA has no information that your products are generally recognized as safe and effective for the above referenced conditions and therefore, the products may also be "new drugs" under section 201 (p) of the Act [21 USC 321(p)]. New drugs may not be legally marketed in the U.S. without prior approval from FDA as described in section 505(a) of the Act [21 USC 355(a)]. FDA approves a new drug on the basis of scientific data submitted by a drug sponsor to demonstrate that the drug is safe and effective.

FDA is aware that Internet distributors may not know that the products they offer are regulated as drugs or that these drugs are not in compliance with the law. Many of these products may be legally marketed as dietary supplements or as cosmetics if therapeutic claims are removed from the promotional materials and the products otherwise comply with all applicable provisions of the Act and FDA regulations.

Under the Act, as amended by the Dietary Supplement Health and Education Act (DSHEA), dietary supplements may be legally marketed with truthful and non-misleading claims to affect the structure or function of the body (structure/function claims), if certain conditions are met. However, claims that dietary supplements are intended to prevent, diagnose, mitigate, treat, or cure disease (disease claims), excepting health claims authorized for use by FDA, cause the products to be drugs. The intended use of a product may be established through product labels and labeling, catalogs, brochures, audio and videotapes, Internet sites, or other circumstances surrounding the distribution of the product. FDA has published a final rule intended to clarify the distinction between structure/function claims and disease claims. This document is available on the Internet at http://vm.cfsan.fda.gov/~lrd/fr000106.html (codified at 21 C.F.R. 101.93(g)).

In addition, only products that are intended for ingestion may be lawfully marketed as dietary supplements. Topical products and products intended to enter into the body directly through the skin or mucosal tissues, such as transdermal or sublingual products, are not dietary supplements. For these products, both disease and structure/function claims may cause them to be new drugs.

Certain over-the-counter drugs are not new drugs and may be legally marketed without prior approval from FDA. Additional information is available in Title 21 of the Code of Federal Regulations (21 CFR) Parts 310 and 330-358, which contain FDA's regulations on over-the-counter drugs. This letter is not intended to be an all-inclusive review of your web site and products your firm may market. It is your responsibility to ensure that all products marketed by your firm are in compliance with the Act and its implementing regulations.

If you need additional information or have questions concerning any products distributed through your web site, please contact FDA. You may reach FDA electronically (e-mail) at APope@CFSAN.FDA.GOV, or you may respond in writing to Angela F. Pope, Compliance Officer, Food and Drug Administration, Division of Compliance and Enforcement, 5100 Paint Branch Parkway, College Park, Maryland 20740-3835. If you have any questions concerning any issue in this letter, please contact Ms. Pope at (301) 436-2375.

Sincerely yours,

/s/

Susan J. Walker, M.D.
Acting Director
Division of Dietary Supplement Programs
Office of Nutritional Products, Labeling and Dietary Supplements
Center for Food Safety and Applied Nutrition

Back to Top

horizonal rule